Navigation Links
ViroPharma to Release 2011 Second Quarter Financial Results on July 28, 2011
Date:7/21/2011

EXTON, Pa., July 21, 2011 /PRNewswire/ -- ViroPharma Incorporated's (Nasdaq: VPHM) second quarter financial results for 2011 are expected to be released on Thursday, July 28, 2011 before the open of the U.S. financial markets.

The company will host a conference call and live audio webcast at 9:00 a.m. Eastern Time on the same day.  During the conference call, ViroPharma management will discuss the 2011 second quarter financial results and other business.

The press release and the live webcast of the conference call will be accessible via ViroPharma's corporate website at http://www.viropharma.com.  An audio archive will be available at the same address until August 18, 2011.  To participate in the conference call, please dial (888) 299-4099 (domestic) and (302) 709-8337 (international).  After placing the call, please tell the operator you wish to join the ViroPharma investor conference call.  

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing novel solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options.  Our goal is to provide rewarding careers to employees, to create new standards of care in the way serious diseases are treated, and to build international partnerships with the patients, advocates, and health care professionals we serve. 

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's website, http://www.viropharma.com/. The company encourages investors to consult these sections for more information on ViroPharma and
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ViroPharma to Present at Three September Healthcare Conferences
2. ViroPharma to Present at Three October Healthcare Conferences
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
5. ViroPharma to Present at Three November Healthcare Conferences
6. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
7. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
8. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
9. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
10. ViroPharma Incorporated Honored by the National Organization for Rare Disorders
11. ViroPharma to Present at Two June Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... July 29, 2015 , ... ... a Silicon Valley-based CRO specializing in Clinical Trial Management. CSSi LifeSciences is specialized ... The core expertise of PRC Clinical is focused on Clinical Trial Management, Clinical ...
(Date:7/29/2015)... Windsor, CT (PRWEB) , ... July 29, 2015 ... ... of Biological Industries’ (BI) advanced cell culture products, announces the availability of BI’s ... Recently launched by Biological Industries, these stem cell differentiation media offer a complete ...
(Date:7/28/2015)... -- A n ew ... developing and commercialising innovative medicines to transform patient quality of ... experienced management team; blue chip ... BioPharma Group Ltd ("Mereo"), a recently-formed speciality biopharmaceutical company, announces ... gross, from blue chip institutional investors and simultaneously acquired a ...
(Date:7/28/2015)... INCLINE VILLAGE, Nev. , July 28, 2015 /PRNewswire/ ... PDLI ) today announced that the Company will release ... ended June 30, 2015, on Wednesday, August 5, 2015, ... call and webcast that day at 4:30 p.m. Eastern ... relating to the call will be available via the ...
Breaking Biology Technology:CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 2Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11PDL BioPharma to Announce Second Quarter 2015 Financial Results on August 5, 2015 2
... 7, 2011 MedWaves, AveCure™ microwave coagulation-ablation (MWA) ... soft-tissue lesions (abnormal structures) safely, effectively, precisely and ... one-thousand patients worldwide, including lesions in bone, kidney, ... bring its technology to treat lesions in other ...
... A whopping portfolio of 16 Nanotechnology products and ... Portfolio Release" organized to mark the fifty-second anniversary ... Releasing the portfolio, Director, Center of Excellence in ... this set of products and processes demonstrates potential ...
... progress in creating digital transistors using a material called ... the material,s use in computers and consumer electronics. ... electricity with little resistance or heat generation. After its ... in physics - it was touted as a potential ...
Cached Biology Technology:MedWaves, Incorporated Announces Receipt of the Chinese State Food and Drug Administration (SFDA) Certification to Import and Sell Its Patented AveCure™ Microwave Ablation System and Devices 2MedWaves, Incorporated Announces Receipt of the Chinese State Food and Drug Administration (SFDA) Certification to Import and Sell Its Patented AveCure™ Microwave Ablation System and Devices 3AIT unveils portfolio of 16 nanotechnology products 2Innovation is step toward digital graphene transistors 2
(Date:7/23/2015)... 23, 2015 Research and Markets ( ... "Global Outlook of the Biometrics Industry 2015 ... The global biometrics market is likely to ... applications owing to the uptake of multiple technologies ... that enhances the growth of biometrics in existing ...
(Date:7/21/2015)... Connecticut , July 21, 2015  NXT-ID, ... "Company"), a biometric authentication company focused on the ... Wocket® smart wallet, announces that it has filed ... System and Method. This invention ... not only authorizes an account, but also the ...
(Date:7/20/2015)... 20, 2015  Acuity Market Intelligence,s latest research ... of Commerce and Privacy" forecasts that between 2014 ... will be downloaded to smart mobile devices by ... market is projected to generate more than $67.9 ... seven-year forecast period.    "Biometrics is ...
Breaking Biology News(10 mins):Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2
... Biology Letters, Steve Brusatte, Professor Michael Benton, and ... did not proliferate immediately after they originated, but that ... driven by two mass extinctions. "The sheer ... was something special about these animals that preordained them ...
... of the gorgeously-decorated fish which throng Australia,s coral reefs and ... may well be written in their genes. Of particular ... able to re-colonise regions of reef devastated by global warming ... move south, says Dr Line Bay of the ARC Centre ...
... A groundbreaking poll finds that almost half of U.S. ... in 10 Americans say they have heard just a ... of synthetic biology, according to a new report released ... D. Hart Research. Both technologies involve manipulating matter ...
Cached Biology News:Mass extinctions and the evolution of dinosaurs 2Fishy future written in the genes 2Fishy future written in the genes 3Nanotech and synbio: Americans don't know what's coming 2
... Lacks the mycobacteria ... the side-effects. For this reason, Incomplete, ... injections. Freund's Adjuvants may be used to produce ... water-in-oil emulsions stimulate high and long-lasting antibody responses ...
Alexa Fluor 350/488/594 Filter Set (Semrock Brightline) *mounted* *Zeiss Axio AF...
PGD2-d4 contains 4 deuterium atoms at the 3, 3', 4, and 4' positions. It is intended for use as an internal standard for the quantification of PGD2 by GC- or LC-mass spectrometry....
ANTI GELSOLIN...
Biology Products: